The fallout from Moon’s confession: 28 content articles in various journals released by Informa were retracted, and one editor resigned. An editor at among the journals published by Sage Publications became suspicious, sparking a thorough and lengthy investigation, which led to the retraction of 60 articles in July 2014. At the ultimate end of 2014, BioMed Central and other publishers alerted the international Committee on Publication Ethics to new types of systematic attempts to manipulate journals’ peer-review processes. According to a statement published on COPE’s website in January 2015, these efforts to hijack the scholarly review system were evidently orchestrated by organizations that initial helped authors write or enhance their scientific articles and sold them favorable peer reviews.4 BioMed Central conducted a comprehensive investigation of all their recently published articles and identified 43 that were published based on evaluations from fabricated reviewers.Introduction of MuGard into France, Eastern and Central European countries, the Benelux countries and the others of European countries is anticipated over another 12 to 18 months. Related StoriesChemotherapy treatment can contribute to long-term neurocognitive deficits in pediatric human brain tumor survivorsClinical trial displays nivolumab drug improves overall survival, standard of living in lung cancers patientsHBV DNA levels guide antiviral treatment in chemotherapy establishing SpePharm is very happy with the commercial release of MuGard thus far, and I am happy to report that preliminary clinician and patient opinions has been very positive, stated Jean-Francois Labbe, SpePharm’s President & CEO.